UBS Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

UBS Group’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$841K	Buy	+20,000	New	+$637K	﹤0.01%	5868
2025 Q4	–	Sell	-42,168	Closed	-$1.17M	–	10478
2025 Q3	$1.17M	Sell	42,168 -41,666	-50%	-$1.05M	﹤0.01%	5430
2025 Q2	$2.04M	Hold	83,834	–	–	﹤0.01%	4797
2025 Q1	$1.74M	Buy	+83,834	New	+$2.11M	﹤0.01%	4821
2021 Q3	–	Sell	-7,959	Closed	-$736K	–	9502
2021 Q2	$736K	Buy	+7,959	New	+$677K	﹤0.01%	4432

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group's ARKG Position: Q2 2026 in Review

UBS Group increased its ARK Genomic Revolution ETF (ARKG) stake by 75% in Q2 2026, buying an estimated $21.6M and bringing the position to 1,585,845 shares worth $66.7M. The position accounts for 0.01% of the portfolio, ranked #1472.

UBS Group first reported a position in ARKG in Q4 2014 and has held it in 41 quarters since. The position peaked at $138M in Q1 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

UBS Group held 1,585,845 shares of ARK Genomic Revolution ETF worth $66.7M as of Q2 2026.
UBS Group bought 678,761 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $21.6M.
ARK Genomic Revolution ETF made up 0.01% of UBS Group's portfolio in Q2 2026, its #1472 holding.
UBS Group first reported a position in ARK Genomic Revolution ETF in Q4 2014 and has held it in 41 quarters since.
UBS Group's ARK Genomic Revolution ETF position peaked at $138M in Q1 2021.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.